Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
http://www.nasdaq.com/symbol/mnta/after-hours
About 8,000 of the 17,000 shares traded after hours (as of 5:50 pm) have been at prices over 15.61.
People buying ahead of the addition to the index or in anticipation of good news?
OPPENHEIMER VIEWS MOMENTA (MNTA) STOCK DROP AS OVERREACTION, KEEPS OUTPERFORM
Analyst Bret Holley tells salesforce Appeals Court for Federal Circuit granted Amphastar/WPI a stay of preliminary injunction that was barring these cos from launching a generic Lovenox. Notes final decision regarding MNTA's claim of patent infringement is still pending. Views outcome as a minor negative for MNTA, as he already expected MNTA's M-enoxaparin would face mkt share erosion from launch of Amphastar/WPI's generic, likely reintroduction of SNY's authorized generic. Maintains MNTA ests, views sharp downside in MNTA on today's decision as overreaction.
Watson confirms court stays injunction, to launch generic Lovenox immediately -- fly on the wall
Wow! Dew certainly has deep pockets I know, I know he doesn't use options.
Zacks opinion on MNTA -- #1 (Aggressive Growth, Strong Buy)
http://www.zacks.com/commentary/19975/Momenta+Pharmaceuticals
I think it is because M. E. Garza lumped ARRY with VRUS and INHX here.
So, I won't be satisfied with anything less than $5 just for its Hep-C program. Throw in the other trials, expect a takeout for $8
http://seekingalpha.com/article/318847-euphoria-from-inhibitex-acquisition-spreads-to-other-firms?source=yahoo
This seems reminiscent of the late 1990's when every company's stock doubled when they said that they had created a web site to sell their stuff.
MNTA stuck at 19.19/19.20 for a while now.
I remember something like this happening 3-4 months back. What happened after that wasn't good
However, Ronny Gal of Bernstein is suggesting that settlement is unlikely (from page 13) --
In short, odds are likely that the patent will hold, but questioned on appeal. The judge did not see substantial merit in the Watson (and Teva) arguments to date. There is a low probability that evidence at trial will reverse his view. At this point, our view is that MNTA has a 70% (or more) probability of winning. We do not see a settlement as likely at this stage as Teva is also involved in the case and the patent may be invalidated by its action (i.e. Momenta has less to gain by settling)
Does Amphastar/Watson have till Jan 24th to decide to accept the offer or to negotiate the terms?
Thanks.
Writing AMRN Puts has been the way to get into the stock.
I wrote AMRN Jan $7 puts for $1 premium. Most likely I keep the premium if AMRN is above $7 by Jan 21st. If not I get it for $6
I also wrote Feb $6 Puts for $0.6 premium on the drop to $6.2 I am pretty sure that I keep this premium, as it is unlikely to drop below $6.
Or $7 if everything breaks against MNTA. I need to buy some PUT protection here . Maybe the Jan 2013 $15 PUT?
http://www.bloomberg.com/news/2012-01-09/novartis-chief-says-he-is-open-to-deals-of-2-billion-to-3-billion.html
They should just buy MNTA for 2.5 Billion
Adam Feuerstein suggests MNTA is a possible takeout candidate for 2012. He also suggests that the other takeout candidates are SGEN, CELG, BMRN, AMAG, ONXX
http://www.thestreet.com/_yahoo/video/11366809/the-next-big-thing-in-biotech-2012-outlook.html?cm_ven=YAHOOV&cm_cat=FREE&cm_ite=NA&s=1#1369025880001
MNTA initiated with an Outperform (Jan 5th) with a price target of $24 by Bernstein.
http://www.theflyonthewall.com/permalinks/entry.php/MNTA;SNY;NVS;TEVAid1290423/MNTA;SNY;NVS;TEVA-Continue-to-view-Momenta-Pharma-as-a-takeover-candidate-says-Rodman--Renshaw
MNTA initiated with an Outperform (Jan 5th) with a price target of $24 by Bernstein.
http://www.theflyonthewall.com/permalinks/entry.php/MNTA;SNY;NVS;TEVAid1290423/MNTA;SNY;NVS;TEVA-Continue-to-view-Momenta-Pharma-as-a-takeover-candidate-says-Rodman--Renshaw
Oppenheimer maintains outperform on MNTA (TheFlyOnTheWall.com)
After Momenta (MNTA) reached a deal with Baxter (BAX) to develop two follow-on biologics, Oppenheimer believes that the deal strengthens Momenta's position in the space. The firm thinks that Momenta is undervalued and its maintains an Outperform rating on the stock.
MNTA is the Rodney Dangerfield of Biotech companies
I understand that. What I meant to say was that this is curious that this followed just 3 days after the Amgen/Watson deal. Maybe they were waiting for Copaxone approval and / or FDA guidance for biosimilars, but then decided to go ahead with it on not so ideal terms (from their perspective) just to eliminate the perception that they were going to be left behind.
Did MNTA rush into this deal because of the Amgen / Watson biosimilars deal? Maybe that deal was the impetus behind MNTA's deal?
Here's the first analyst comment from today.
Leerink Swann believes that Momenta's (MNTA) partnership with Baxter (BAX) for the development of at least two biosimilar products will effectively combine the companies' strengths and enable parallel product development efforts. The firm maintains an Outperform rating on Momenta.
So, they could have been working on this for a year, perhaps? Maybe more? So, in that context, doesn't the 9% royalty or at the most a 20% royalty if it is interchangeable and the sole generic seem low?
Maybe there will be some short covering tomorrow. There are still 5.7 million shares short as of Nov 30th (maybe more when the data comes out for Dec 15th?).
http://www.nasdaq.com/symbol/mnta/short-interest
If I can write covered calls for Jan 2012 $19 or possibly even the $20 strike prices and get 0.50 cents or better, I will be happy
Thomas A. Maher owns an 8.4% passive stake in GKK as of today. That would put his stake at 4.25 Million shares considering 50.53 as the total number of shares.
http://beta.theflyonthewall.com/permalinks/entry.php/GKKid1493120/GKK-Gramercy-Capital-may-consider-sale-after-debt-restructuring-Bloomberg-reports
It looks like two of the catalysts listed have not materialized. Maybe it is too early to tell whether Horizant is a bust. Also, it looks like it will be approved in Japan next year.
I am thinking of just acquiring a few hundred shares at this point, write puts for a few hundred more. If it comes down some more, then I will write more puts, especially if the premium is still high.
http://seekingalpha.com/article/269243-xenoport-favorable-risk-reward-ratio
mcBio, biomaven,
Are you guys adding to XNPT under $4? How much of a loss is the failed Parkinson's drug trial?
You can sell the Mar 12 $4 puts for around 55 cents now, which is a 14% return for 3 1/2 months or you are put the stock at 3.45. I am thinking of doing this next week.
They have $2.91/share in cash. Although my guess is that they will burn that rather quickly if their sales for Horizant doesn't pick up soon.
Thanks.
Possibly a new short position established? It seemed to push the stock down to 15.48 at the end from around 15.75. Who knows?
I guess the Nov numbers are down a little because of the competition from Sanofi's temporary AG. Hope it picks back up right away in December.
FDA Proposes Biosimilar and Interchangeable Biological Product User Fee System and Performance Goals
I saw this on a twitter message by acgood / BioDueDiligence
http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2011/12/fda-proposes-biosimilar-and-interchangeable-biological-product-user-fee-system-and-performance-goals.html
MNTA upgraded to BUY by TheStreet.com. Hey, we will take it even if it is just TheStreet.com
http://www.thestreet.com/story/11331575/1/momenta-pharmaceuticals-inc-stock-upgraded-mnta.html
Someboday tell me it is one these four things
1. Copaxone approval (probably not as TEVA is up 2.5%)
2. Winning the copaxone patent case against TEVA (probably not as TEVA is up 2.5%)
3. Amphastar PI stay rejected in the appeals court
4. FOB Partnership
Almost 1.6 million shares yesterday. Maybe it was Oppenheimer or some other fund selling some of their MNTA shares?
Certainly is behaving weird last few days. Up 8% on no news now, not that I am complaining
There seems to be something more than that. It is trading as if some news is coming soon. Almost 715k shares and it is just noon. Maybe a 1.5 million+ day today.
MNTA has been frustrating to say the least. Why is this down today? Maybe Mouton will find something and post it here?
y3maxx, 1 million shorts who shorted MNTA under $15 will have to cover soon
http://www.nasdaq.com/symbol/mnta/short-interest
Has Mylan done any clinical trials on their version of Copaxone for their FDA application? Does anybody know? Thanks.
Rockrat, thanks for your analysis. From the table of contents in the document, doesn't the inequitable conduct case seem to be rather strong for MNTA? This is pretty harsh stuff about Dr. Pinchasi. This is just from a cursory glance of the table of contents
FINDINGS OF FACT AND CONCLUSIONS OF LAW RELATING TO
DEFENDANTS’ INEQUITABLE CONDUCT DEFENSE ......................... 222
...
...
(v) Dr. Pinchasi’s Intent to Deceive ....................................................... 260
(1) Dr. Pinchasi’s Lacked Credibility .................................................... 260
(2) Dr. Pinchasi’s Documents Do Not Establish Good Faith ..................... 262
(3) Dr. Pinchasi’s Motive to Lie to the PTO ............................................ 269
(4) Dr. Pinchasi Took Inconsistent Positions With the FDA and PTO ........ 273
C.Conclusions of Law ................................................................. 277
(i) The Materiality of the April 1994 Data Table and the RBL
Degranulation Information........................................................... 277
(ii) Dr. Pinchasi Had An Intent to Deceive the PTO ......................... 285
Awesome. Thanks. Now let us see if it can push through the resistance at 15.28 that Tekcor was mentioning
MNTA should PR this so that the mixup can be rectified
Legal experts here -- Any idea what this is? Why is it being interpreted as good news?
http://www.cafc.uscourts.gov/images/stories/opinions-orders/2012.1062.11-16-11.1.pdf
That is too bad! I was selling $2.5 covered calls and getting 0.15 cents for it each time. Now there is no way of lowering your purchase price any more.
ARRY Options?
I am guessing that Nov options for ARRY will be the last. Any ideas as to why they may be getting rid of options for ARRY? Not much interest in them?